SMi is delighted to announce the 13th annual ADMET conferencereturning to London on the 9th - 10th July 2018.
Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.
The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.
The 13th annual ADMET conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling softwares to the validation of humanised mice models.
Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:
ADME/PK Optimisation for Drug Design and Discovery
In Vitro to Human In Vivo Translation
Physiologically Based PK Modeling
DMPK, PBPK, PKPD
Accurate First-in-Human Dose Predictions
Transporters, Bioavailability, Formulation
In vivo / in vitro / in silico
Hazard and Safety Assessment
Preclinical Pharmacology Testing